CONDITION EDUCATION · PRELIMINARY CONDITION-SPECIFIC EVIDENCE
INOCA & Coronary Microvascular Dysfunction: Circulation and EECP Evidence
INOCA means ischaemia with non-obstructive coronary arteries. It describes myocardial ischaemia in the setting of normal or non-obstructive coronary arteries; it is not a single mechanism and it is not a conclusion that can be drawn from symptoms alone. Coronary microvascular dysfunction (CMD) is one important mechanism within the INOCA spectrum, while epicardial coronary spasm is another. The distinction matters because an angiogram that does not show an obstructive large-vessel lesion does not by itself explain the cause of symptoms or establish an individual diagnosis.
CLAIM 2 — ESTABLISHED
Claim 2 — ESTABLISHED: Circulation in INOCA and CMD
In INOCA, a mismatch between myocardial oxygen demand and coronary blood supply can occur without an obstructive blockage in the large coronary arteries. CMD and epicardial coronary spasm are recognized pathophysiologic mechanisms of that mismatch.[1][2]
CMD concerns the function of the coronary microcirculation—the small vessels that help regulate blood flow within the heart muscle. The EAPCI consensus describes two broad, potentially overlapping mechanisms in microvascular angina: structural microvascular remodelling, which can reduce microcirculatory conductance and oxygen-delivery capacity, and functional arteriolar dysregulation, in which impaired vasodilation or vasoconstriction can limit flow when myocardial demand rises. The American Heart Association similarly explains that damage to the inner walls of small coronary vessels can be associated with spasm and reduced blood flow.[1][3]
This circulation mechanism is clinically important, but INOCA is heterogeneous. CMD is not present in every person with INOCA, and CMD and vasospasm may coexist. Tests that assess coronary flow reserve, myocardial blood flow, perfusion, or vasomotor function are interpreted by clinical teams in their full clinical context; a normal or non-obstructive angiogram alone does not rule out all coronary vascular mechanisms.[1][2]
CLAIM 1 — STRONG
Claim 1 — STRONG: EECP’s therapy-level circulation effect
Enhanced external counterpulsation (EECP), also called external counterpulsation (ECP), is a noninvasive, ECG-timed cuff therapy.
EECP uses cuffs around the calves and thighs that are synchronized to the electrocardiogram. The cuffs inflate sequentially during diastole and deflate before the next systole. This timing produces diastolic augmentation and, in directly studied EECP physiology, is associated with increased diastolic coronary perfusion pressure and venous return; deflation before systole reduces vascular resistance and assists systolic unloading.[4]
That is a therapy-level circulation statement, not a condition-specific outcome claim. The timing and hemodynamic effect are established features of the intervention, but they do not establish that EECP treats, cures, prevents, reverses, or is suitable for any individual with INOCA or CMD. Whether a therapy-level circulation effect translates into outcomes depends on the studied population, comparator, outcome, and follow-up—and, for INOCA/CMD, the direct evidence is limited as described below.
Keep the claims separate: EECP’s ECG-timed diastolic inflation and systolic deflation describe a studied circulation mechanism. They do not by themselves demonstrate clinical efficacy for every INOCA endotype or for any particular person.
EVIDENCE BOX — CLAIM 3
EECP for INOCA & Coronary Microvascular Dysfunction: Preliminary
Evidence tier: PRELIMINARY. Completed direct evidence consists of two small, single-centre randomized studies in selected CMD populations with non-obstructive coronary disease; neither establishes outcomes across the heterogeneous INOCA population. Wang and colleagues reported a prospective study of 83 people with angina or dyspnoea, documented ischaemia, non-obstructive coronary arteries, and coronary flow reserve (CFR) below 2.0 at one Chinese centre. Participants were reported as assigned to EECP (41) or control (42); both groups received aspirin, atorvastatin, and nicorandil. After four weeks, the EECP group had a higher transthoracic-Doppler CFR than the control group, along with changes in endothelial biomarkers and symptom/quality-of-life measures. Zhang and colleagues reported a 2024 randomized study of 80 people with nonobstructive coronary artery disease and CMD defined by cardiac-MRI myocardial perfusion reserve below 2.0. Forty participants received EECP in addition to conventional drugs and cardiac rehabilitation, and 40 received the base treatment. The abstract reports better post-treatment measures described as effective rate, LVEF, NO, and VEGF, and fewer adverse cardiovascular events in the EECP-plus-rehabilitation group. What these studies can support: They are direct, short-term evidence in defined CMD populations that measured circulation-related or patient-reported outcomes differed in the studied EECP groups compared with the study controls. What they cannot support: They do not establish benefit for all people with INOCA, all CMD or vasospastic endotypes, clinical-event reduction, long-term durability, or individual suitability. The Wang study was single-centre, small (83 participants), short (four weeks), had no sham treatment, relied partly on symptom/quality-of-life outcomes, and reported no long-term clinical-event outcome. Although the paper calls the design prospective and randomized, its published methods do not describe allocation-concealment safeguards or participant/provider blinding. The Zhang study also remains preliminary: it evaluated EECP added to cardiac rehabilitation rather than EECP alone; it was small and apparently single-centre; and the accessible report does not provide sufficiently transparent endpoint definitions, event counts, follow-up duration, or blinding/allocation safeguards to support broad efficacy, durability, clinical-event, or individual-suitability conclusions. Both selected populations should not be generalized automatically to INOCA populations with different mechanisms or coexisting disease. A separate later publication is a study protocol, not an efficacy result: it plans a 110-participant, single-centre, open-label, outcome-assessor-blinded randomized trial of EECP plus optimal medical therapy versus optimal medical therapy in people with coronary artery disease and CMD, with cardiac-MRI perfusion outcomes and six-month follow-up. Its authors state that whether EECP improves CMD remained unknown when the protocol was published. It adds no completed efficacy evidence and includes a broader CAD population rather than establishing evidence specific to INOCA.[5][8][6]
SAFETY AND CLINICAL BOUNDARIES
Urgent and safety boundary
This page must not be used to explain away chest discomfort or other possible heart-attack warning signs. If you have heart-attack warning signs, call 911 right away—even if you are not sure it is a heart attack. The American Heart Association identifies chest discomfort, shortness of breath, discomfort in the upper body, cold sweat, nausea, lightheadedness, and unusual fatigue as possible heart-attack warning signs. INOCA/CMD education is not emergency assessment, and a prior non-obstructive angiogram does not determine the cause of a new or changing symptom episode.[7]
EECP is not an emergency intervention, a substitute for urgent assessment, or a way to determine individual treatment eligibility. The cited EECP review describes clinical exclusions and precautions that depend on factors such as rhythm triggering, bleeding risk, vascular conditions, valve disease, blood pressure, and heart-failure stability; these are reasons an education page cannot decide suitability.[4]
CONTINUE LEARNING
Choose the next useful educational step.
COMMON QUESTIONS
Frequently asked questions
What does INOCA mean?
INOCA is short for ischaemia with non-obstructive coronary arteries. It is a clinical term for myocardial ischaemia in the setting of normal or non-obstructive coronary arteries. CMD and epicardial coronary spasm are among the mechanisms clinicians may evaluate; INOCA is not one single disease mechanism.[1][2]
Is coronary microvascular dysfunction the same as INOCA?
No. CMD is one possible mechanism within the INOCA spectrum. INOCA can also involve epicardial coronary spasm, and mechanisms can overlap. The terms should not be used to infer an individual diagnosis or a single treatment path.[1]
Does a non-obstructive angiogram mean symptoms are not cardiac?
No. The EAPCI consensus notes that CMD and vasospasm can contribute to myocardial ischaemia without obstructive coronary artery disease, and that symptoms should not automatically be classified as non-cardiac solely because angiography is non-obstructive. Determining the cause of symptoms requires clinical assessment.[1]
What has EECP been directly studied for in CMD/INOCA?
Two small, selected CMD studies directly examined EECP in non-obstructive coronary disease populations. One reported higher CFR and better angina-related measures after EECP versus its control cohort; the other tested EECP added to cardiac rehabilitation and reported post-treatment differences in several study measures. This is preliminary evidence—not proof of benefit for all INOCA endotypes, long-term outcomes, or any individual.[5][8]
Why is an urgent safety boundary included on an education page?
Chest discomfort and related symptoms can have time-sensitive causes. The page separates educational discussion of INOCA/CMD from urgent assessment because the cause of a new or worsening episode cannot be determined by this content or by a past test result.[7]
REFERENCES
Sources
- Kunadian et al., EAPCI INOCA expert consensus
- American College of Cardiology microvascular dysfunction resource
- American Heart Association coronary microvascular disease resource
- Sharma, Ramsey, and Tak, EECP clinical-practice review
- Wang et al., EECP and coronary flow reserve in CMD
- Cao et al., EECP-CMD II trial protocol
- American Heart Association heart-attack warning signs
- Zhang, Yin, and Ren, EECP plus cardiac rehabilitation in NOCAD/CMD